NYSEAMERICAN:ATNM - Actinium Pharmaceuticals Stock Price, Forecast & News

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) issued its earnings results on Monday, March, 16th. The biotechnology company reported ($0.17) EPS for the quarter, beating the Zacks' consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.

Actinium Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Actinium Pharmaceuticals.

3 equities research analysts have issued twelve-month price objectives for Actinium Pharmaceuticals' stock. Their forecasts range from $1.50 to $5.00. On average, they expect Actinium Pharmaceuticals' stock price to reach $3.25 in the next year. This suggests a possible upside of 1,193.8% from the stock's current price. View Analyst Price Targets for Actinium Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.

Media headlines about ATNM stock have trended somewhat positive this week, InfoTrie reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Actinium Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Actinium Pharmaceuticals.

Actinium Pharmaceuticals saw a decrease in short interest in January. As of January 31st, there was short interest totalling 2,310,000 shares, a decrease of 34.0% from the January 15th total of 3,500,000 shares. Based on an average daily trading volume, of 3,350,000 shares, the days-to-cover ratio is currently 0.7 days. Approximately 1.5% of the company's shares are sold short. View Actinium Pharmaceuticals' Current Options Chain.

Some companies that are related to Actinium Pharmaceuticals include Senesco Technologies (ELOX), CorMedix (CRMD), CorMedix (CRMD), Burcon NutraScience (BU), Ampliphi Biosciences (APHB), Immutep (IMM), 22nd Century Group (XXII), MediGene (MDG1), OncoCyte (OCX), OncoCyte (OCX), Novoheart (NVH), Verseon (VSN), Imugene (IMU), Faron Pharmaceuticals Oy (FARN) and Arix Bioscience (ARIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Opko Health (OPK), TransEnterix (TRXC), Sorrento Therapeutics (SRNE), Tandem Diabetes Care (TNDM), Cancer Genetics (CGIX), Align Technology (ALGN) and Inovio Pharmaceuticals (INO).

Actinium Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (0.60%), Virtu Financial LLC (0.25%) and UBS Group AG (0.11%). Company insiders that own Actinium Pharmaceuticals stock include Ajit Shetty, Dale L Ludwig, Sandesh Seth and Steve O'loughlin. View Institutional Ownership Trends for Actinium Pharmaceuticals.

ATNM stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC and UBS Group AG. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Ajit Shetty, Dale L Ludwig, Sandesh Seth and Steve O'loughlin. View Insider Buying and Selling for Actinium Pharmaceuticals.

Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ATNM stock can currently be purchased for approximately $0.25.

Actinium Pharmaceuticals has a market capitalization of $41.24 million. Actinium Pharmaceuticals employs 30 workers across the globe.View Additional Information About Actinium Pharmaceuticals.

The official website for Actinium Pharmaceuticals is http://www.actiniumpharmaceuticals.com/.

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.